Auranofin Exerts Antibacterial Activity Against Neisseria Gonorrhoeae in a Female Mouse Model of Genital Tract Infection

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2022 Apr 21

PMID 35446884

Authors

Ahmed E M Elhassanny

Nader S Abutaleb

Mohamed N Seleem

Affiliations

Soon will be listed here.

Abstract

Neisseria gonorrhoeae has been classified by the U.S. Centers for Disease Control and Prevention as an urgent threat due to the rapid development of antibiotic resistance to currently available antibiotics. Therefore, there is an urgent need to find new antibiotics to treat gonococcal infections. In our previous study, the gold-containing drug auranofin demonstrated potent in vitro activity against clinical isolates of N. gonorrhoeae, including multidrug-resistant strains. Therefore, the aim of this study was to investigate the in vivo activity of auranofin against N. gonorrhoeae using a murine model of vaginal infection. A significant reduction in N. gonorrhoeae recovered from the vagina was observed for infected mice treated with auranofin compared to the vehicle over the course of treatment. Relative to the vehicle, after three and five days of treatment with auranofin, a 1.04 (91%) and 1.40 (96%) average log10-reduction of recovered N. gonorrhoeae was observed. In conclusion, auranofin has the potential to be further investigated as a novel, safe anti-gonococcal agent to help meet the urgent need for new antimicrobial agents for N. gonorrhoeae infection.

Citing Articles

Evaluation of the activity of antimicrobial peptides against bacterial vaginosis.

Kang X, Zhao T, Song Y, Zhang J, Yuan T, Han Q Open Life Sci. 2024; 19(1):20220927.

PMID: 39091626 PMC: 11292031. DOI: 10.1515/biol-2022-0927.

Substituted salicylic acid analogs offer improved potency against multidrug-resistant Neisseria gonorrhoeae and good selectivity against commensal vaginal bacteria.

Almolhim H, Elhassanny A, Abutaleb N, Abdelsattar A, Seleem M, Carlier P Sci Rep. 2023; 13(1):14468.

PMID: 37660222 PMC: 10475031. DOI: 10.1038/s41598-023-41442-5.

Making a chink in their armor: Current and next-generation antimicrobial strategies against the bacterial cell envelope.

Kaderabkova N, Mahmood A, Furniss R, Mavridou D Adv Microb Physiol. 2023; 83:221-307.

PMID: 37507160 PMC: 10517717. DOI: 10.1016/bs.ampbs.2023.05.003.

Vertebrate and Invertebrate Animal and New In Vitro Models for Studying Biology.

Girgis M, Christodoulides M Pathogens. 2023; 12(6).

PMID: 37375472 PMC: 10301118. DOI: 10.3390/pathogens12060782.

The Optimal Management of Infections.

Ursu R, Luchian I, Damian C, Porumb-Andrese E, Cobzaru R, Nichitean G Microorganisms. 2022; 10(12).

PMID: 36557641 PMC: 9784239. DOI: 10.3390/microorganisms10122388.

References

Warner D, Shafer W, Jerse A . Clinically relevant mutations that cause derepression of the Neisseria gonorrhoeae MtrC-MtrD-MtrE Efflux pump system confer different levels of antimicrobial resistance and in vivo fitness. Mol Microbiol. 2008; 70(2):462-78. PMC: 2602950. DOI: 10.1111/j.1365-2958.2008.06424.x. View

Liu Y, Liu W, Russell M . Suppression of host adaptive immune responses by Neisseria gonorrhoeae: role of interleukin 10 and type 1 regulatory T cells. Mucosal Immunol. 2013; 7(1):165-76. PMC: 3812424. DOI: 10.1038/mi.2013.36. View

Elkashif A, Seleem M . Investigation of auranofin and gold-containing analogues antibacterial activity against multidrug-resistant Neisseria gonorrhoeae. Sci Rep. 2020; 10(1):5602. PMC: 7101410. DOI: 10.1038/s41598-020-62696-3. View

Camara J, Serra J, Ayats J, Bastida T, Carnicer-Pont D, Andreu A . Molecular characterization of two high-level ceftriaxone-resistant Neisseria gonorrhoeae isolates detected in Catalonia, Spain. J Antimicrob Chemother. 2012; 67(8):1858-60. DOI: 10.1093/jac/dks162. View

Woods C . Gonococcal infections in neonates and young children. Semin Pediatr Infect Dis. 2005; 16(4):258-70. DOI: 10.1053/j.spid.2005.06.006. View

Seong Y, Alhashimi M, Mayhoub A, Mohammad H, Seleem M . Repurposing Fenamic Acid Drugs To Combat Multidrug-Resistant Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2020; 64(7). PMC: 7318036. DOI: 10.1128/AAC.02206-19. View

Lovett A, Duncan J . Human Immune Responses and the Natural History of Infection. Front Immunol. 2019; 9:3187. PMC: 6389650. DOI: 10.3389/fimmu.2018.03187. View

Abutaleb N, Seleem M . In vivo efficacy of auranofin in a hamster model of Clostridioides difficile infection. Sci Rep. 2021; 11(1):7093. PMC: 8007812. DOI: 10.1038/s41598-021-86595-3. View

Bradford P, Miller A, ODonnell J, Mueller J . Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of , Including Multi-Drug-Resistant Isolates. ACS Infect Dis. 2020; 6(6):1332-1345. DOI: 10.1021/acsinfecdis.0c00021. View

10.

Abdelkhalek A, Abutaleb N, Mohammad H, Seleem M . Antibacterial and antivirulence activities of auranofin against Clostridium difficile. Int J Antimicrob Agents. 2018; 53(1):54-62. PMC: 6475173. DOI: 10.1016/j.ijantimicag.2018.09.018. View

11.

Ohnishi M, Golparian D, Shimuta K, Saika T, Hoshina S, Iwasaku K . Is Neisseria gonorrhoeae initiating a future era of untreatable gonorrhea?: detailed characterization of the first strain with high-level resistance to ceftriaxone. Antimicrob Agents Chemother. 2011; 55(7):3538-45. PMC: 3122416. DOI: 10.1128/AAC.00325-11. View

12.

BLODGETT Jr R, Pietrusko R . Long-term efficacy and safety of auranofin: a review of clinical experience. Scand J Rheumatol Suppl. 1986; 63:67-78. View

13.

Raterman E, Jerse A . Female Mouse Model of Neisseria gonorrhoeae Infection. Methods Mol Biol. 2019; 1997:413-429. DOI: 10.1007/978-1-4939-9496-0_24. View

14.

Streeter P, Corbeil L . Gonococcal infection in endotoxin-resistant and endotoxin-susceptible mice. Infect Immun. 1981; 32(1):105-10. PMC: 350594. DOI: 10.1128/iai.32.1.105-110.1981. View

15.

Rowley J, Vander Hoorn S, Korenromp E, Low N, Unemo M, Abu-Raddad L . Chlamydia, gonorrhoea, trichomoniasis and syphilis: global prevalence and incidence estimates, 2016. Bull World Health Organ. 2019; 97(8):548-562P. PMC: 6653813. DOI: 10.2471/BLT.18.228486. View

16.

Jerse A, Wu H, Packiam M, Vonck R, Begum A, Garvin L . Estradiol-Treated Female Mice as Surrogate Hosts for Neisseria gonorrhoeae Genital Tract Infections. Front Microbiol. 2011; 2:107. PMC: 3129519. DOI: 10.3389/fmicb.2011.00107. View

17.

St Cyr S, Barbee L, Workowski K, Bachmann L, Pham C, Schlanger K . Update to CDC's Treatment Guidelines for Gonococcal Infection, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(50):1911-1916. PMC: 7745960. DOI: 10.15585/mmwr.mm6950a6. View

18.

Foerster S, Gustafsson T, Brochado A, Desilvestro V, Typas A, Unemo M . The first wide-scale drug repurposing screen using the Prestwick Chemical Library (1200 bioactive molecules) against Neisseria gonorrhoeae identifies high in vitro activity of auranofin and many additional drugs. APMIS. 2019; 128(3):242-250. DOI: 10.1111/apm.13014. View

19.

Picker M, Knoblock R, Hansen H, Bautista I, Griego R, Barber L . Notes from the Field: First Case in the United States of Neisseria gonorrhoeae Harboring Emerging Mosaic penA60 Allele, Conferring Reduced Susceptibility to Cefixime and Ceftriaxone. MMWR Morb Mortal Wkly Rep. 2020; 69(49):1876-1877. PMC: 7737691. DOI: 10.15585/mmwr.mm6949a5. View

20.

Harbut M, Vilcheze C, Luo X, Hensler M, Guo H, Yang B . Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc Natl Acad Sci U S A. 2015; 112(14):4453-8. PMC: 4394260. DOI: 10.1073/pnas.1504022112. View